C-Rad Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

C-Rad heeft een totaal eigen vermogen van SEK310.2M en een totale schuld van SEK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk SEK450.1M en SEK139.9M. De EBIT C-Rad is SEK66.4M waardoor de rentedekking -13.8 is. Het heeft contanten en kortetermijnbeleggingen van SEK118.7M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

SEK 0

Schuld

Rente dekkingsratio	-13.8x
Contant	SEK 118.70m
Aandelen	SEK 310.20m
Totaal verplichtingen	SEK 139.90m
Totaal activa	SEK 450.10m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Sentiment Still Eluding C-Rad AB (publ) (STO:CRAD B)

Oct 24

Market Participants Recognise C-Rad AB (publ)'s (STO:CRAD B) Earnings Pushing Shares 29% Higher

Jun 02

Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts

Jan 30

C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue

Jul 03

Will the Promising Trends At C-Rad (STO:CRAD B) Continue?

Mar 05

Are C-Rad's (STO:CRAD B) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 07

What Percentage Of C-Rad AB (publ) (STO:CRAD B) Shares Do Insiders Own?

Jan 17

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK399.4M ) CRAD B } overtreffen de korte termijn passiva ( SEK127.2M ).

Langlopende schulden: De kortetermijnactiva CRAD B ( SEK399.4M ) overtreffen de langetermijnschulden ( SEK12.7M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: CRAD B is schuldenvrij.

Schuld verminderen: CRAD B had 5 jaar geleden geen schulden.

Schuldendekking: CRAD B heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: CRAD B heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

C-Rad Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

C-Rad AB (publ) to Report Q3, 2025 Results on Oct 23, 2025

Independent Director recently bought kr190k worth of stock

Price target decreased by 14% to kr49.00

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sentiment Still Eluding C-Rad AB (publ) (STO:CRAD B)

CEO & President recently bought kr85k worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Market Participants Recognise C-Rad AB (publ)'s (STO:CRAD B) Earnings Pushing Shares 29% Higher

Investor sentiment improves as stock rises 16%

C-Rad AB (publ) Appoints Mats Thorén as Board Member

Full year 2023 earnings: EPS and revenues exceed analyst expectations

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Returns On Capital Are A Standout For C-Rad (STO:CRAD B)

C-Rad's (STO:CRAD B) Earnings Are Weaker Than They Seem

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Do C-Rad's (STO:CRAD B) Earnings Warrant Your Attention?

Price target increased by 12% to kr58.00

C-Rad AB (publ)'s (STO:CRAD B) Popularity With Investors Is Clear

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

Price target increased by 13% to kr65.50

Third quarter 2023 earnings: Revenues exceed analyst expectations

Is Now The Time To Look At Buying C-Rad AB (publ) (STO:CRAD B)?

Investor sentiment improves as stock rises 19%

Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

Consensus EPS estimates fall by 14%

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased by 11% to kr57.75

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

Are Investors Undervaluing C-Rad AB (publ) (STO:CRAD B) By 45%?

Price target decreased to kr62.50

C-Rad AB (publ) Announces CFO Changes

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analyst expectations

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Feb 02, 2024

Price target decreased to kr62.50

C-RAD Launches New Updated eDucation Portal as an Online Platform

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analyst expectations

Is Now An Opportune Moment To Examine C-Rad AB (publ) (STO:CRAD B)?

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

Chief Financial Officer recently bought kr93k worth of stock

Consensus EPS estimates fall by 41%

Price target decreased to kr72.50

First quarter 2022 earnings: Revenues miss analyst expectations

Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

Insufficient new directors

Insufficient new directors

Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts

Full year 2021 earnings: EPS and revenues miss analyst expectations

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

Price target increased to kr82.00

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold kr625k worth of stock

Second quarter 2021 earnings released

C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

Will the Promising Trends At C-Rad (STO:CRAD B) Continue?

C-RAD and Alliance Radiation Oncology Announce That Alliance Has Become the First Center in the Greater Northshore Area to Integrate C-Rad

New 90-day high: kr60.30

President of China exercised options to buy kr1.5m worth of stock.

Are C-Rad's (STO:CRAD B) Statutory Earnings A Good Reflection Of Its Earnings Potential?

C-Rad and With-Global Engages in a Partnership for the South Korean Market